Combination of ibrutinib plus venetoclax with MRD-driven duration of treatment results in a higher rate of MRD negativity in IGHV unmutated than mutated CLL: updated interim analysis of FLAIR Study
Munir, T. Pitchford, A. Bloor, Adrian Pettitt, A. Patten, P. E. M. Forconi, F. Schuh, A. Fox, C. P. Gatto, S. Kennedy, B.
Munir, T.
Pitchford, A.
Bloor, Adrian
Pettitt, A.
Patten, P. E. M.
Forconi, F.
Schuh, A.
Fox, C. P.
Gatto, S.
Kennedy, B.
Citations
Altmetric:
Abstract
Authors
Munir, T.
Pitchford, A.
Bloor, Adrian
Pettitt, A.
Patten, P. E. M.
Forconi, F.
Schuh, A.
Fox, C. P.
Gatto, S.
Kennedy, B.
Gribben, J.
Pemberton, N.
Sheehy, O.
Preston, G.
Howard, D.
Hockaday, A.
Cairns, D.
Jackson, S.
Greatorex, N.
McWhirter, N.
Shingles, J.
Cwynarski, K.
Paneesha, S.
Allsup, D.
Rawstron, A.
Hillmen, P.
Pitchford, A.
Bloor, Adrian
Pettitt, A.
Patten, P. E. M.
Forconi, F.
Schuh, A.
Fox, C. P.
Gatto, S.
Kennedy, B.
Gribben, J.
Pemberton, N.
Sheehy, O.
Preston, G.
Howard, D.
Hockaday, A.
Cairns, D.
Jackson, S.
Greatorex, N.
McWhirter, N.
Shingles, J.
Cwynarski, K.
Paneesha, S.
Allsup, D.
Rawstron, A.
Hillmen, P.
Affiliation
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Munir T, Pitchford A, Bloor A, Pettitt A, Patten PEM, Forconi F, et al. Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study. Blood. 2022 Nov;140. PubMed PMID: WOS:000893223200095.